| |  Online-Ressource |
|---|
| Verfasst von: | Shah, Neil P. [VerfasserIn]  |
|---|
| | García-Gutiérrez, Valentín [VerfasserIn] |
|---|
| | Jiménez-Velasco, Antonio [VerfasserIn] |
|---|
| | Larson, Sarah M. [VerfasserIn] |
|---|
| | Saußele, Susanne [VerfasserIn] |
|---|
| | Rea, Delphine [VerfasserIn] |
|---|
| | Mahon, François-Xavier [VerfasserIn] |
|---|
| | Levy, Moshe Yair [VerfasserIn] |
|---|
| | Gómez-Casares, María Teresa [VerfasserIn] |
|---|
| | Mauro, Michael J. [VerfasserIn] |
|---|
| | Sy, Oumar [VerfasserIn] |
|---|
| | Martin-Regueira, Patricia [VerfasserIn] |
|---|
| | Lipton, Jeffrey H. [VerfasserIn] |
|---|
| Titel: | Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response |
|---|
| Titelzusatz: | final 5-year analysis of DASFREE: original paper |
|---|
| Verf.angabe: | Neil P. Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M. Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Michael J. Mauro, Oumar Sy, Patricia Martin-Regueira, Jeffrey H. Lipton |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | September 2023 |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffentlicht: 29. Mai 2023 ; Gesehen am 29.02.2024 |
|---|
| Titel Quelle: | Enthalten in: British journal of haematology |
|---|
| Ort Quelle: | Oxford [u.a.] : Wiley-Blackwell, 1955 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 202(2023), 5 vom: Sept., Seite 942-952 |
|---|
| ISSN Quelle: | 1365-2141 |
|---|
| Abstract: | Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE study (ClinicalTrials.gov; NCT01850004), the 2-year TFR rate after dasatinib discontinuation was 46%; here we present the 5-year update. Patients with a stable DMR after ≥2 years of dasatinib therapy discontinued treatment and were followed for 5 years. At a minimum follow-up of 60 months, in 84 patients discontinuing dasatinib, the 5-year TFR rate was 44% (n = 37). No relapses occurred after month 39 and all evaluable patients who relapsed and restarted dasatinib (n = 46) regained a major molecular response in a median of 1.9 months. The most common adverse event during the off-treatment period was arthralgia (18%, 15/84); a total of 15 withdrawal events were reported in nine patients (11%). At the 5-year final follow-up, almost half of the patients who discontinued dasatinib after a sustained DMR maintained TFR. All evaluable patients who experienced a relapse quickly regained a DMR after restarting dasatinib, demonstrating that dasatinib discontinuation is a viable and potentially long-term option in patients with CML-CP. The safety profile is consistent with the previous report. |
|---|
| DOI: | doi:10.1111/bjh.18883 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1111/bjh.18883 |
|---|
| | kostenfrei: Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.18883 |
|---|
| | DOI: https://doi.org/10.1111/bjh.18883 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | chronic phase chronic myeloid leukaemia |
|---|
| | dasatinib |
|---|
| | deep molecular response |
|---|
| | major molecular response |
|---|
| | treatment-free remission |
|---|
| K10plus-PPN: | 1882174402 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response / Shah, Neil P. [VerfasserIn]; September 2023 (Online-Ressource)
